CedeƱo, Genevy A.
HRN: 21-82-37 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/20/2022
CO-AMOXICLAV 625MG (TAB)
08/20/2022
08/27/2022
PO
625mg
BID X 7 Days
Post Partum With Second Degree RMLE; PROM X 8 Hours
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes